Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Primary adrenal melanoma is an exceedingly rare diagnosis. We present a case of primary left adrenal melanoma with rapid and extensive distant metastasis. The patient underwent a biopsy of the left adrenal tumor, and pathological analysis confirmed malignant melanoma. Immunohistochemical staining revealed positive cytoplasmic reactivity for Melan A, HMB45, and SOX-10. We also review relevant cases reported in the English literature and discuss the diagnostic criteria, differential diagnoses, and potential management strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390801 | PMC |
| http://dx.doi.org/10.3389/fonc.2025.1654218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary adrenal melanoma with extensive metastasis: a case report and literature review.
Front Oncol
August 2025
Department of Radiology, Second Hospital of Tianjin Medical University, Tianjin, China.
Primary adrenal melanoma is an exceedingly rare diagnosis. We present a case of primary left adrenal melanoma with rapid and extensive distant metastasis. The patient underwent a biopsy of the left adrenal tumor, and pathological analysis confirmed malignant melanoma.
View Article and Find Full Text PDFAdrenal Insufficiency Induced by Checkpoint Inhibitor Therapy in a Patient With Metastatic Acral Melanoma: A Case Report.
Cureus
August 2025
General Medicine, King's College Hospital National Health Service (NHS) Foundation Trust, London, GBR.
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced melanoma; however, their clinical benefit is tempered by a widening spectrum of immune-related adverse events (irAEs), including endocrine dysfunction. Among these, hypophysitis and adrenal insufficiency remain under-recognised, yet potentially life-threatening complications. We describe a case of secondary adrenal insufficiency in a 78-year-old female with unresectable Stage IIIC acral melanoma treated with nivolumab and relatlimab.
View Article and Find Full Text PDFDiagnostic value of F-FDG PET/CT in the follow-up of conjunctival melanoma.
Ann Nucl Med
August 2025
Department of Ophthalmology, Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital Northwest University, Xi'an, 710004, China.
Objective: To evaluate the diagnostic performance of F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in detecting metastatic conjunctival melanoma (CM).
Methods: This retrospective study enrolled 67 patients with histopathologically confirmed CM who underwent F-FDG PET/CT for follow-up or suspected recurrence. Parameters including short-axis diameter of lesions, maximum standardized uptake value (SUVmax), the target-to-nontarget (T/NT) ratios of cervical lymph nodes, and bone lesion characterization (osteolytic, osteoblastic, or unchanged) were evaluated.
Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0).
Eur J Pharmacol
October 2025
College of Pharmacy, Jinan University, Guangzhou, China; State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. Electronic address:
In 2022, the FDA approved nivolumab-relatlimab for the treatment of unresectable or metastatic melanoma. In the present study, we conducted a living pharmacovigilance study, integrating data from clinical trials and the FDA Adverse Event Reporting System (FAERS) database, to assess the safety profile of nivolumab-relatlimab. Treatment related adverse events (TRAEs) in trials of nivolumab-relatlimab available in electronic databases were systematically searched.
View Article and Find Full Text PDFThe Safety and Efficacy of Anti-LAG-3 for Patients with Melanoma: A Systematic Review and Meta-analysis Study.
Anticancer Agents Med Chem
July 2025
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Introduction: Melanoma, an aggressive skin cancer, has seen treatment advancements with immune checkpoint inhibitors (ICIs) like ipilimumab and nivolumab. Despite improved survival rates, resistance remains a challenge. The recent focus on lymphocyte activation gene-3 (LAG-3) inhibitors, such as relatlimab, shows promise in combination therapies, potentially improving outcomes with fewer adverse effects.
View Article and Find Full Text PDF